1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62(1): 10-29.
2. Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z. Outcome of breast cancer in Iran: a study of Tehran Cancer Registry data. Asian Pac J Cancer Prev. 2008; 9(2): 275-278.
3.Raymond KN, Pierre VC. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem. 2005; 16(1): 3-8.
4.Loomans-Kropp HA, Umar A, Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precis Oncol. 2019; 3: 3.
5.Shahbazi-Gahrouei D, Moradi Khaniabadi P, Moradi Khaniabadi B, Shahbazi-Gahrouei S. Medical imaging modalities using nanoprobes for cancer diagnosis. A literature review on recent findings. J Res Med Sci. 2019; 24: 38.
6.Joan Estelrich, María Jesús Sánchez-Martín, Maria Antònia Busquets. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 2015; 10: 1727–1741.
7.Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 2010; 6(3): 430-437.
8.Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem. 2007; 7(4): 425-440.
9.Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ. In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: potential MR imaging contrast agents for cancer. J Magn Reson Imaging. 2001; 14(2):169-174.
10.Monika A. Cywińska, Ireneusz P. Grudziński, Andrzej Cieszanowski, Michał Bystrzejewski, Magdalena Popławska. Pol J Radiol. 2011; 76(2): 28–36.
11.Luke J. Leman, Bruce E. Maryanoff, and M. Reza Ghadiri. Molecules that Mimic Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis. J Med Chem. 2014; 57(6): 2169–2196.
12.Sangram Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, and Andras Lacko, Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy. Front Pharmacol. 2018; 9: 1154.
13.Alan T Remaley, Marcelo Amar, Dmitri Sviridov. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008; 6(9): 1203–1215.
14. Lacko AG, Sabnis NA, Nagarajan B, McConathy WJ. HDL as a drug and nucleic acid delivery vehicle. Front Pharmacol. 2015; 6: 247.
15.Ma X, Song Q, Gao X. Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery. Acta Pharm Sin B. 2018; 8(1): 51-63.
16.Bijsterbosch MK, Van Berkel TJ. Lactosylated high density lipoprotein: a potential carrier for the site-specific delivery of drugs to parenchymal liver cells. Mol Pharmacol. 1992; 41(2): 404-411.
17.McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008; 19(2): 183-188.
18.Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond). 2013; 8(6): 875-890.
19.Gong M, Zhang Q, Zhao Q, Zheng J, Li Y, Wang S, Yuan Y. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy. Drug Deliv. 2019; 26(1): 708-716.
20.Wang T, Subramanian C, Yu M, White PT, Kuai R, Sanchez J, Moon JJ, Timmermann BN, Schwendeman A, Cohen MS. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer. Surgery. 2019. pii: S0039-6060(19)30349-30356.
21.Emily E. Morin, Xiang-An Li, Anna Schwendeman. HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Front Endocrinol (Lausanne). 2018; 9: 715.
22.Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002; 22(4): 2045-2049.
23.Kenneth K. Ng, Jonathan F. Lovell, Gang Zheng. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Acc Chem Res. 2011; 44(10): 1105–1113.
24.Yang M, Chen J, Cao W, Ding L, Ng KK, Jin H, Zhang Z, Zheng G. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine (Lond). 2011; 6(4): 631-641.
25. Mirzaei M, Mehravi B, Ardestani MS, Ziaee SA, Pourghasem p. In Vitro Evaluation of Gd3+-Anionic Linear Globular Dendrimer-Monoclonal Antibody: Potential Magnetic Resonance Imaging Contrast Agents for Prostate Cancer Cell Imaging. Mol Imaging Biol. 2015; 17(6): 770-776.
26.Rui M, Guo W, Ding Q, Wei X, Xu J, Xu Y. Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int J Nanomedicine. 2012; 7: 3751-3768.
27.Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging. 2001; 14(4): 457-463.